Characterising an aromatase inhibitor resistant breast cancer cell line
نویسندگان
چکیده
منابع مشابه
Characterising an aromatase inhibitor resistant breast cancer cell line
Introduction Aromatase inhibitors (AI) are a novel adjuvant endocrine treatment for estrogen receptor (ER)-positive, postmenopausal breast cancer. They function by inhibiting the aromatase enzyme that converts androgens into estrogens. AIs have demonstrated excellent efficacy in clinical trials and have shown supremacy over Tamoxifen. However, prolonged use of AIs can lead to acquired resistanc...
متن کاملAromatase inhibitor strategies in metastatic breast cancer
Despite ongoing therapeutic innovations, metastatic breast cancer (MBC) remains a treatable but incurable disease. In the developed world, a diagnosis of MBC without a preceding diagnosis of early stage disease is a rare event. However, approximately one-third of women with early stage breast cancer ultimately experience a distant recurrence. Because the majority of breast cancers express estro...
متن کاملMolecular Docking of Curcumin With Breast Cancer Cell Line Proteins
Background: Breast cancer is known as the most widely recognized dangerous tumors; therefore, the most common reason for mortality among all instances of harmful neoplastic illness in females. This is because the lack of specific signs and symptoms at the early stage and at the aggressive nature. Currently, breast cancer treatment such as chemotherapy, surgery and radiotherapy has not been effe...
متن کاملProfiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer
Aromatase inhibitor (AI) resistance during breast cancer treatment is mimicked by MCF-7:5C (5C) and MCF-7:2A (2A) cell lines that grow spontaneously. Survival signaling is reconfigured but cells are vulnerable to estradiol (E2)-inducible apoptosis. These model systems have alterations of stress related pathways including the accumulation of endoplasmic reticulum, oxidative, and inflammatory str...
متن کاملEnhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer.
BACKGROUND We have found that the platelet-derived growth factor receptor (PDGFR)/Abl signaling pathway is up-regulated as a determinant of the acquisition of resistance to estrogen deprivation in vitro. We aimed to determine its clinical relevance in aromatase inhibitor (AI)-resistant breast cancer. PATIENTS AND METHODS We identified a cohort of 45 patients with estrogen receptor-positive br...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Proceedings
سال: 2012
ISSN: 1753-6561
DOI: 10.1186/1753-6561-6-s4-p3